225641-84-9

Usage

Uses

Used in Pharmaceutical Industry:
Carbamic acid, [(1R,3S)-3-hydroxycyclopentyl]-, 1,1-dimethylethyl ester (9CI) is used as a pharmaceutical intermediate for the synthesis of various drugs and medications. Its unique structure and reactivity make it a valuable component in the development of new pharmaceutical compounds, contributing to the advancement of medical treatments and therapies.
As a pharmaceutical intermediate, Carbamic acid, [(1R,3S)-3-hydroxycyclopentyl]-, 1,1-dimethylethyl ester (9CI) plays a crucial role in the synthesis of drugs with specific therapeutic properties. Its ability to be modified and incorporated into more complex molecular structures allows for the creation of novel drugs with improved efficacy and reduced side effects. Carbamic acid, [(1R,3S)-3-hydroxycyclopentyl]-, 1,1-dimethylethyl ester (9CI)'s versatility and potential applications in the pharmaceutical industry make it an important asset in the ongoing quest for new and better medications.

Upstream product

• 108-05-4 vinyl acetate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 201054-55-9 (+)-(1R,4S)-1-hydroxy-4-[(tert-butoxycarbonyl)amino]-2-cyclopentene 
• 99027-90-4 2-oxa-3-azabicyclo[2.2.1]hept-5-ene-3-carboxylic acidtert-butyl ester 
• 1036260-18-0 (1S,3R)-3-aminocyclopentane-1-ol 

Downstream Products

• 225641-86-1 tert-butyl (R)-(3-oxocyclopentyl)carbamate 
• 124555-33-5 (1S,3R)-3-aminocyclopentan-1-ol hydrochloride 
• 225641-88-3 [(1R,3S)-3-(4-Cyano-4-phenyl-piperidin-1-yl)-cyclopentyl]-carbamic acid tert-butyl ester 
• 225641-89-4 [(1R,3R)-3-(4-Cyano-4-phenyl-piperidin-1-yl)-cyclopentyl]-carbamic acid tert-butyl ester 
• 754963-28-5 1-((1S,3R)-3-Amino-cyclopentyl)-4-phenyl-piperidine-4-carbonitrile 

Relevant academic research and scientific papers

POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS

Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.

COMPOUNDS USEFUL AS PROTEIN KINASES INHIBITORS

The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, co

Preparation and evaluation of 1,3-diaminocyclopentane-linked dihydropyrimidinone derivatives as selective α(1a)-receptor

Several 1,3-diaminocyclopentane linked α(1a)-receptor antagonists were prepared using a divergent chemical strategy that allows for rapid analysis of all stereochemical permutations for their effect on α1-receptor binding. (C) 2000 Published by Elsevier Science Ltd.